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 Abstract 
 Introduction: Mortality in dialysis patients is higher than in the general population, and car-
diovascular disease represents the leading cause of death. Hypertension and volume overload 
are important risk factors for the development of left ventricular hypertrophy (LVH) in hemo-
dialysis (HD) and peritoneal dialysis (PD) patients. Other factors are mainly represented by hy-
perparathyroidism, vascular calcification, arterial stiffness and inflammation. The aim of this 
study was to compare blood pressure (BP) and metabolic parameters with cardiovascular 
changes [cardiothoracic ratio (CTR), aortic arch calcification (AAC) and LV mass index (LVMI)] 
between PD and HD patients.  Materials and Methods: 45 patients (23 HD and 22 PD patients) 
were enrolled. BP measurements, echocardiography and chest X-ray were performed in each 
patient to determine the LVMI and to evaluate the CTR and AAC. Inflammatory indexes, intact 
parathyroid hormone (iPTH)  and  arterial blood gas analysis were also evaluated.  Results: LVMI 
was higher in PD than HD patients (139 ± 19 vs. 104 ± 22; p = 0.04). In PD patients, a significant 
correlation between iPTH, C-reactive protein and the presence of LVH was observed (r = 0.70, 
p = 0.04; r = 0.70, p = 0.03, respectively). The CTR was increased in PD patients as compared 
to HD patients, while no significant differences in cardiac calcifications were determined.  Con-
clusions: Our data indicate that HD patients present more effective BP control than PD pa-
tients. Adequate fluid and metabolic control are necessary to assess the adequacy of BP, which 
is strongly correlated with the increase in LVMI and with the increased CTR in dialysis patients. 
PD is a home therapy and allows a better quality of life, but PD patients may present a further 
increased cardiovascular risk if not adequately monitored.  © 2014 S. Karger AG, Basel 
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 Introduction 
 Considering the reduced overall survival of patients with renal failure on dialysis, it 
appears clinically relevant to stratify the morbidity and mortality risk factors, with particular 
attention to cardiovascular risk  [1, 2] . This is usually due to the presence of well-known 
conditions, such as arterial hypertension, diabetes mellitus, ageing and dyslipidemia, and to 
several complications, such as volume overload, uremic cardiomyopathy and vascular damage 
with arterial stiffness and vascular calcification  [3–5] . The prevalence of hypertension in 
dialysis patients is particularly high. Mean arterial blood pressure (BP) and cardiovascular 
morbidity are strongly related  [6, 7] . The Netherlands Cooperative Study on the Adequacy of 
Dialysis showed that systolic BP (SBP) is an independent predictor of mortality and an indi-
cator of fluid overload in dialysis patients. In particular,  two specific causes of hypertension 
are often present: increased arterial stiffness and fluid overload  [8–11] . Hypertension and 
hypervolemia can result in an increase in the left ventricular (LV) afterload and may lead to 
an increase in LV wall thickness, although this condition alone fails to explain LV hypertrophy 
(LVH). Also, LVH is not always correlated with the severity of hypertension and hypervolemia 
in dialysis patients  [3, 12–17] . Another possible cause of LVH may be the increased cardiac 
output state produced by high-flow arteriovenous fistula, or anemia, as well as the direct 
effect of hyperparathyroidism  [16, 17] . A link between abnormalities of mineral metabolism 
and LVH has been previously described. In fact, intact parathyroid hormone (iPTH) exerts 
direct trophic effects on cardiac myocytes and fibroblasts resulting in intramyocardial arterial 
wall thickening, LVH and myocardial fibrosis  [18–20] . These effects were shown by in vitro 
studies where PTH induced chronotropic, inotropic as well as hypertrophic effects on cardio-
myocytes. In this light, Katoh et al.  [21] and Saleh et al.  [22] described a positive inotropic 
action played by PTH on the isolated papillary muscle of the rat heart with direct evidence of 
a hypertrophic effect of PTH. This condition was also shown on adult ventricular cardiomyo-
cytes  [23] . Furthermore, vascular calcification that accompanies secondary hyperparathy-
roidism (SHPT) in end-stage renal disease (ESRD) leads to an increased arterial resistance 
and induces the formation of LVH  [24–26] . Other factors, such as oxidative stress, inappro-
priate activation of the renin-angiotensin-aldosterone system and inflammation, may also 
play a role in LV growth in ESRD  [27] . Persistent activation of the inflammatory response has 
been recognized as an important independent risk factor for the development of cardiovas-
cular complications in dialysis patients  [28] . The pathophysiological mechanisms by which 
inflammation might contribute to the development of ventricular hypertrophy are still not 
completely understood. Inflammation may promote the development of LVH by changes in 
the function and morphology of vascular smooth muscle cells that increase arterial stiffness 
 [27, 28] . Additionally, subclinical inflammation can lead to LVH by altering the equilibrium 
that regulates cell growth, apoptosis, phenotype and matrix turnover of cardiac tissue. 
However, it was shown that inflammation predicts future increase in BP, suggesting that 
increased inflammatory state may precede the increase in BP  [29] . Assessment of these condi-
tions and constant research on new serum blood markers and instrumental parameters in 
patients with ESRD appear mandatory to reduce the high cardiovascular morbidity and 
mortality  [30, 31] .
 The cardiothoracic ratio (CTR) is an easily available parameter from routine posterior-
anterior chest radiographs. It usually indicates the LV size and may provide reasonable esti-
mates of vascular calcification  [32] .
 The aim of this study was to compare BP and metabolic parameters with cardiovascular 
abnormalities [CTR, aortic arch calcification (AAC) and LV mass index (LVMI)] between a 
group of peritoneal dialysis (PD) and a group of hemodialysis (HD) patients.
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 Materials and Methods 
 Study Design 
 We performed an observational study, between October 2009 and April 2013, on 45 clinically stable 
patients on a dialysis program at the University Hospital ‘Policlinico Umberto I’ of Rome, Sapienza University 
of Rome, Italy. The sample size is based on similar experiences from studies conducted in only one single 
center  [33, 34] .
 The study protocol was approved by the local ethics committee. The study conforms with the principles 
outlined in the Declaration of Helsinki.
 Patients 
 Inclusion Criteria.  We included consecutive patients aged  ≥ 18 years with stable clinical and biochemical 
conditions in a HD or PD program for at least 3 months.
 Exclusion Criteria. Patients who refused to give consent for participation were excluded. Patients with 
underlying malignancy, hepatic insufficiency or alcoholism, chronic obstructive pulmonary disease, inter-
current acute illness and/or major infections and severe heart failure (ejection fraction <35%) were not 
included. Patients with a technically inadequate image on echocardiography, the presence of hemodynami-
cally significant valvular disease or pericardial effusion were also excluded.
 Measurements 
 Clinical examinations of HD patients were performed during the middle of the week, before HD 
treatment, while PD patients were examined before the first replacement of the morning with an empty peri-
toneum. Height and weight were measured with the patient wearing indoor clothing before starting intra-
peritoneal dialysate infusions at routine visits. Body mass index (BMI) was calculated using the formula of 
[weight (kg)/height (m 2 )].
 Laboratory Measurements.  Blood was drawn in the morning after an overnight fast of at least 12 h, 
before HD treatment. In all patients, the levels of fasting plasma glucose, hemoglobin (mg/dl), hematocrit, 
calcium (mg/l), phosphorus (mg/l), total serum cholesterol (mg/dl), high-density lipoprotein (HDL; mg/dl), 
low-density lipoprotein (LDL; mg/dl), triglycerides (mg/dl), creatinine (mg/dl), urea nitrogen (mg/dl), 
albumin (g/dl), sodium (mE/l), potassium (mEq/l) and C-reactive protein (CRP) were measured by standard 
automated techniques. Serum albumin (g/dl) was determined by the bromocresol purple method. PTH was 
determined by a two-site assay that measures ‘intact’ hormone. The calcium phosphate product was calcu-
lated using serum calcium concentrations, corrected for serum albumin concentration. Renal function was 
estimated using the MDRD (modification of diet in renal disease) formula. LDL cholesterol was calculated 
using the Friedewald equation: LDL (mg/dl) = total cholesterol  − HDL  − (triglycerides/5). Arterial blood gas 
analysis was performed by a blood gas analyzer (Nova Phox Plus C).
 BP Measurements.  Clinic BP measurements were made 3 times after 10 min of rest in a seated position 
using a standard sphygmomanometer and cuffs adapted to the arm circumference according to the British 
Hypertension Society guidelines, and the mean values for SBP and diastolic BP (DBP) were calculated for all 
participants. SBP and DBP levels were measured in PD and HD patients before and after the dialysis session 
at routine visits in a fasting state. The SBP and DBP levels were taken as the points of appearance and disap-
pearance of Korotkoff sounds, respectively. Hypertension was defined by elevated SBP (>140 mm Hg), DBP 
(>90 mm Hg) and median arterial BP readings on repeated measurements and on different days.
 X-Ray Measurements.  Chest X-ray was used to evaluate the CTR, and it was performed before the HD 
session and in a fasting state for PD patients. We used technically adequate posterior-anterior chest X-ray, 
with defined borders and a defined heart aortic arch. Three adjudicators independently assessed technical 
adequacy, with disagreements resolved by consensus. Standard chest radiographs were taken in a standing 
position in the anterior-posterior view and the CTR was measured based on these radiographs. The CTR was 
calculated as the ratio of the maximum transverse cardiac diameter in millimeters to the maximum thoracic 
diameter in millimeters. We defined a normal CTR value as less than 0.5  [29, 30] .
 Assessment of Aortic Calcification Using Chest X-Ray.  The grade of AAC using a previously validated 
scoring system was assessed: grade 0 (no visible calcification), grade 1 (small spots of calcification or single 
thin calcification of the aortic handle), grade 2 (one or more areas of thick calcification) and grade 3 (circular 
calcification of the aortic knob).  All measurements of AAC and CTR were assessed independently by three 
adjudicators, with disagreements resolved by a consensus measurement  [31, 32] .
 Echocardiography.  Transthoracic echocardiography was performed before the HD session and after 
emptying the peritoneal cavity in PD patients. M-mode 2D echocardiographic examinations were completed by 
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a single experienced sonographer in the echocardiography laboratory using a standard institutional protocol. 
Commercially available instruments (Toshiba Aplio xV, Toshiba American Medical Systems, Inc., Tustin, Calif., 
USA) equipped with 2.25- to 7.5-MHz imaging transducers were used; the subjects were in the left decubitus 
position, and the sonographer was blinded to all clinical details of the patients. All echocardiographic data were 
recorded according to the guidelines of the American Society of Echocardiography (ASE). The end-diastolic and 
end-systolic LV internal diameter, interventricular septum thickness and posterior wall thickness were measured. 
The LV mass (LVM) was estimated by Devereux’s formula normalized by body surface area and height  [35–38] .
 Statistical Analysis 
 Data management and analysis were performed using IBM ® SPSS ® Statistics 17 for Windows ® software 
(IBM Corporation, Armonk, N.Y., USA). The normality of the variables was tested using the Shapiro-Wilk 
method for normal distributions. All continuous variables were expressed as means ± standard deviation and 
categorical variables were expressed as numbers (percentages). Student’s t test, Mann-Whitney U test, and 
Fisher’s exact test were performed to determine differences between groups, as appropriate. The binomial 
test or χ 2 test was used for comparison of categorical data. Pearson’s or Spearman’s correlation was applied 
to determine the relationship and the strength of the association between the variables in bivariate corre-
lation. A probability value of p < 0.05 was considered statistically significant.
Male n (%) 19 (42.2)
Age, years 64.5 ± 12
Body weight, kg 67.4 ± 12.5
Height, cm 167 ± 8.5
BMI 23.7 ± 2.7
Hb, g/dl 12.7 ± 1.5
Glycemia, mg/dl 77.6 ± 5.7
Creatinine, mg/dl 7.1 ± 2.7
BUN, mg/dl 71 ± 21.9
eGFR, ml/min 5.8 ± 4.3
Sodium, mEq/l 141 ± 2.2
Potassium, mEq/l 4.3 ± 0.6
Calcium, mg/dl 9.1 ± 0.5
Phosphorus, mg/dl 3.5 ± 0.5
Ca × P, mg2/dl2 31.4 ± 4.5
 Total cholesterol, mg/dl 157.9 ± 26.8
HDL, mg/dl 44.4 ± 12.5
LDL, mg/dl 123.5 ± 20.6
Triglycerides, mg/dl 135.1 ± 50.6
Iron, μg/dl 77.6 ± 29.3
Ferritin, ng/ml 117.3 ± 80.1
Transferrin, mg/dl 258.3 ± 46.5
Uric acid, mg/dl 4.3 ± 0.9
CRP, mg/dl 0.2 ± 0.1
Albumin, g/dl 4 ± 0.7
APD 9
CAPD 13
HD 10
HDF online 5
AFB 8
Dialysis time, years 4.5 ± 2.6
 Data are shown as means ± SD or number (%). Hb = Hemoglobin; 
BUN = blood urea nitrogen; eGFR = estimated glomerular filtration rate; 
APD = automated peritoneal dialysis; CAPD = continuous ambulatory 
peritoneal dialysis; HDF online = hemodiafiltration online; AFB = acetate 
free biofiltration.
 Table 1.  Baseline characteristics 
of the patients (n = 45)
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 Results 
 Patient Characteristics 
 The study included 23 patients (9 males, 14 females) from the Hemodialysis Unit and 22 
patients (10 males, 12 females) from the Peritoneal Dialysis Unit at our clinic. We enrolled 
the entire population of patients at our clinic to represent all the patients treated. The mean 
age of the 2 groups was 64.5 ± 12 years. The cause of ESRD was chronic glomerulonephritis 
in 10 patients, diabetic nephropathy in 9 patients, autosomal dominant polycystic kidney 
disease in 4 patients, hypertensive nephrosclerosis in 12 patients and unknown in 10 patients.
 Table 1 shows the general characteristics of the study participants. In particular, 18 
patients (7 on PD and 11 on HD) were taking antihypertensive drugs with a previously good 
BP control and 14 patients were smokers. Antihypertensive, antiplatelet and statin therapies 
were continued in the patients included in the study.
 There were no statistically significant differences in age, sex, height, weight, BMI, serum 
sodium, potassium, calcium, phosphorus, Ca × P product, glucose, Hg, HDL, triglycerides, pH 
and concentration of bicarbonates between the groups. The mean values of SBP, DBP and 
median arterial BP were significantly higher in PD patients compared to HD patients (p = 
0.019, p = 0.017 and p = 0.007, respectively;  fig. 1 ) as well as the LVMI (p = 0.037;  fig. 2 ).
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 Fig. 1. Box-and-whisker plots.
 a SBP in PD patients versus HD 
patients.  b DBP in PD patients 
versus HD patients.  c Median ar-
terial BP (MAP) in PD patients 
versus HD patients. • = Outliers. 
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 Fig. 2. Bar charts with error bars. 
The mean value of LVMI was sig-
nificantly higher in PD patients 
compared with HD patients ( * p = 
0.037). Boxes represent means; 
error bars indicate ±2 SD. 
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 A significant correlation was observed between iPTH, CRP levels and the presence of LVH 
in PD patients (r = 0.70, p = 0.04 and r = 0.70, p = 0.03, respectively;  fig. 3 ,  4 ). However, no 
correlations of serum Ca or P with LVMI were obtained. Also, the CTR was increased in PD 
patients (CTR >0.5 in 15/22 PD patients; CTR >0.5 in 7/23 HD patients) (p = 0.001), but no 
significant correlations with AAC were observed.
 Discussion 
 Although the use of dialysis procedures significantly improved the outcomes of ESRD 
patients, dialysis patients still die prematurely, being early cardiovascular disease the leading 
cause of death  [1, 3] . Clinical studies have reported a high prevalence of cardiac abnormalities 
in dialysis patients, particularly the presence of LVH.
 These cardiac alterations result from arterial hypertension and volume overload, asso-
ciated with a number of metabolic and neurohormonal abnormalities. However, LVH is not 
always correlated with the severity of hypertension and hypervolemia  [1, 3, 6, 9, 39] .
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LVMI versus iPTH in PD patients 
(r = 0.704, p = 0.041). 
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 Fig. 4. Linear regression plot. 
LVMI versus CRP in PD patients
(r = 0.701, p = 0.032). 
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 In our study, the mean values of BP, LVMI and CTR were significantly higher in PD patients 
compared with HD patients. The greater frequency of arterial hypertension in PD patients 
may be due to the greater hydration state, considering that these patients are susceptible to 
extracellular volume expansion, and evidence indicates that PD patients have a greater fluid 
overload than HD patients  [1, 3, 6, 16] .
 The absence of overt fluid retention in the physical examination is, by itself, insufficient 
to exclude significant hypervolemia. Clinically, dry weight is estimated by trial and error with 
less accuracy in the adjustment of dry weight, also due to the continuous changes in the peri-
toneal membrane  [3, 6, 40, 41] . Adequacy of PD is traditionally assessed using K t /V urea and 
total creatinine clearance; however, this approach underestimates the importance of fluid 
overload  [1, 3] .
 The bodily distribution of excess fluid is different between HD and PD patients. Overhy-
dration in PD patients is mainly present in the subcutaneous tissue, while blood volume 
overload in HD patients is generally the cause of body weight gain during the interdialytic 
period (48–72 h), due to the consumption of foods and liquids, and of a reduction during the 
session (4 h) by a rapid ultrafiltration from the intravascular compartment and a slow ultra-
filtration from the interstitial space through refilling. Usually, the PD technique is continually 
executed, and balance is obtained between the different compartments in a continuous way 
by the ultrafiltration from the interstitial space  [6] . HD patients present a greater hydration 
state before the dialysis session, but it decreases after the session, with subsequent increases 
up to the next session, reflecting the changes in PD  [42] .
 Moreover, many errors can occur in estimating LV volume or LVM because these param-
eters are influenced by volume overload and by body weight. Therefore, it appears essential 
to perform studies using echocardiography at the same time as the HD session  [3] . We 
performed transthoracic echocardiography before the HD session, and after emptying the 
peritoneal cavity in PD patients. Also, patients undergoing automated PD, which has a higher 
fluid removal capacity than continuous ambulatory PD (CAPD), were only partially protected. 
In fact, in our study, no significant differences between patients treated with CAPD and 
patients on automated PD were observed.
 Long-term CAPD is disadvantageous for the preservation of cardiac performance, and it 
is associated with the greatest LVMI compared to both short-term CAPD and HD  [42] . In this 
light, several studies showed that long-term CAPD patients have a greater volume overload 
and more severe LVH than HD patients  [38–40] . This may explain the higher prevalence of 
and more severe LVH observed in PD patients, with a mean time from the start of dialysis of 
4 ± 2 years. This seems to be related to the reduction of the residual renal function that may 
also play a role in limiting the increase in LVMI by improving the removal of uremic toxins 
 [43] .
 In addition to the effects of BP and volume, several nonhemodynamic factors influence 
LVM in dialysis patients. In fact, we also observed a correlation between iPTH, CRP levels, the 
CTR and the presence of LVH in PD patients.
 The International Pediatric Peritoneal Dialysis Network (IPPN) registry collects detailed 
prospective clinical and echocardiographic information, which has recently been analyzed in 
detail and showed that hyperparathyroidism was independently associated with LVH. In 
addition to the well-known PTH target organs [44], PTH receptors have also been identified 
in the heart and in the vascular system, and in vitro, PTH induced hypertrophy of cardiomyo-
cytes and arteriolar wall thickening  [22] .
 The mechanisms by which PTH interacts on myocardial tissue, directly or indirectly, have 
been investigated in several models. Bogin et al.  [45] showed in an experimental model that 
PTH causes a rise in heart rate. A similar finding was reported in 1993 by Wang et al.  [46] 
indicating that PTH causes contraction in isolated ventricular myocytes from neonatal rats. 
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This result was also confirmed in a study performed on isolated papillary muscles of rat 
hearts  [23] . Additionally, there is evidence of a hypertrophic effect of PTH on isolated cardio-
myocytes from adult rats  [22] . Furthermore, Amann et al.  [24] showed that PTH seems to 
have a permissive role in fibroblast activation in nephrectomized and parathyroidectomized 
rats inducing intramyocardial fibrosis. Furthermore, SHPT may contribute to vascular 
dysfunction, with increased arterial stiffness, which may lead to persistent increases in BP 
 [25] .
 Continuous activation of the inflammatory response is an important independent risk 
factor for the development of cardiovascular abnormalities in dialysis patients. Wang et al. 
 [28] showed that chronic microinflammation, through its association with progressive arte-
riosclerosis, participates in the maintenance of hemodynamic overload limiting the efficacy 
of therapeutic interventions  [27] . Recent studies reported an inverse relationship between 
CRP and other inflammatory mediators and renal function, suggesting that uremia per se may 
contribute to the inflammatory response, although the exact mechanism is not completely 
clear  [47] . In this light, in murine models altered TNF and IL-1 clearance was described in 
nephrectomized rats  [48] .
 In our study, an independent association was observed between CRP and LVH in PD 
patients, but the exact mechanism of this association is not clear. CRP may be considered as 
a marker of LVH or of the increased inflammatory state, and LVH may be correlated to the 
presence of volume overload. Indeed, volume overload is a frequent complication in PD 
patients and is itself associated with immune activation leading to an increased production 
of proinflammatory cytokines  [28] . Volume overload can worsen arterial hypertension, which 
is associated with more severe LVH. Thus, volume overload may in part explain the associ-
ation between inflammation and LVH. However, some studies have shown that inflammation 
may precede the increase in BP. Inflammation and SHPT may promote arterial stiffness that 
contributes to LVH and cardiomegaly. In fact, the CTR significantly correlates with CRP and 
LVH in PD patients. It is an easily available parameter from a routine posterior-anterior chest 
radiograph that usually indicates the LV size and may provide reasonable estimates of 
vascular calcifications. Although cardiomegaly lacks specificity in identifying the cardiac 
lesion, its presence has a strong prognostic significance in patients with a high cardiovascular 
risk.
 Gao et al.  [49] reported that ΔCTR is an important prognostic factor in PD patients. In our 
study, the CTR was increased in PD patients. PD appears to have clear advantages, consid-
ering the possibility of performing the treatment at home, improving patients’ quality of life. 
Surprisingly, only two studies comparing the quality of life of HD and PD patients are available: 
the North Thames Dialysis Study  [50] and Broadening Options for Long-Term Dialysis in the 
Elderly (BOLDE)  [51] . The survival rate, however, is usually longer in HD patients, especially 
in older diabetic patients. Vascular access, intradialytic hypotension, which may relate to 
myocardial dysfunction, and impaired autonomic function with hemodynamic instability, 
bleeding and amyloidotic arthropathy represent the most critical aspects of HD treatment. 
Furthermore, we should consider that PD is a less expensive treatment than HD  [52, 53] . 
However, PD patients should be constantly monitored with clinical and instrumental tools, 
including bioelectrical impedance, CTR and echocardiogram, since they are at increased risk 
of developing volume overload and cardiovascular disorders  [54] , as confirmed by the present 
study. Larger clinical trials are needed to confirm our results.
 Limitations 
 Our study presents a relatively small, selective cohort of HD and PD patients, and the lack 
of correlation in the HD group may be due to the small sample size. Therefore, a larger popu-
lation is warranted. Also, our study is based on associations with surrogate end points; the 
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generated hypothesis needs further prospective follow-up studies with stronger end points 
to show causality. Furthermore, as shown in our results, a significant proportion of the 
patients were on antihypertensive and statin therapies and they were smokers. In this sense, 
the potential impact of hypertension, hypercholesterolemia and their treatments may have 
possibly confounded the results.
 Conclusion 
 Arterial hypertension and LVH are important clinical features in PD patients. Adequate 
fluid control to assess the adequacy of BP control is necessary, and it is well correlated with 
the increase in LVMI and CTR in PD patients. HD patients have a better control of BP with a 
significantly lower LVMI compared to PD patients. Other factors such as hyperparathyroidism 
and inflammation may also play a role in LVH. The CTR is easily obtainable by chest radiog-
raphy and correlates with inflammation and LVH.
 Further elucidations on the etiology of cardiomegaly and on the presence of calcifications 
are necessary and may require second-level surveys with the use of echocardiography and/
or cardiac CT scan.
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